Stockscreener 앱 받기
1.77
0.00%
0.00
시간 외 거래:
1.79
0.02
+1.13%
전일 마감가:
$1.77
열려 있는:
$1.67
하루 거래량:
4.21M
Relative Volume:
1.21
시가총액:
$386.18M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-6.3214
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
-7.81%
1개월 성능:
-6.84%
6개월 성능:
+34.09%
1년 성능:
+18.79%
1일 변동 폭
$1.63
$1.82
1주일 범위
$1.63
$1.99
52주 변동 폭
$0.80
$2.89
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.77 | 386.18M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
149.10 | 67.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.38 | 46.50B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.27 | 44.66B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.94 | 15.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.72 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment - Investing.com Australia
Akebia Therapeutics' (AKBA) Xoanacyl Receives EMA Panel Endorsem - GuruFocus
Akebia says kidney drug endorsed in EU (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months - MarketScreener
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com UK
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Jefferies Initiates Coverage of Akebia Therapeutics (AKBA) with Buy Recommendation - Nasdaq
Jefferies sets Akebia Therapeutics stock at Buy, $6 price target By Investing.com - Investing.com Canada
Jefferies Initiates Akebia Therapeutics at Buy With $6 Price Target - MarketScreener
Akebia initiated with a Buy at Jefferies - TipRanks
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - MSN
Piper Sandler maintains Akebia stock with $6 price target By Investing.com - Investing.com Canada
Akebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025 - Nasdaq
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewswire
Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results - Stock Titan
Akebia Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - MSN
Akebia Stock Drops 28% On Pricing Of $50M Common Stock Offering - Barchart
Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - MSN
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock - Nasdaq
Akebia Therapeutics Announces Public Offering Pricing - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33% - Simply Wall St
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale - TradingView
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Akebia Therapeutics Prices $50 Million Public Offering -March 20, 2025 at 04:19 am EDT - Marketscreener.com
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
‘Buckle Up for Another Surge,’ Says Cowen About Nvidia Stock - The Globe and Mail
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
2 No-Brainer Biotech Stocks to Buy Right Now - The Globe and Mail
SEC Form 424B5 filed by Akebia Therapeutics Inc. - Quantisnow
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Akebia Therapeutics announces proposed public offering of common stock -March 19, 2025 at 04:57 pm EDT - Marketscreener.com
Akebia Therapeutics launches public stock offering - Investing.com
Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? - Insider Monkey
Akebia Therapeutics dives on stock offering plans - TradingView
Akebia Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors - StockTitan
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.30%
4.98%
자본화:
|
볼륨(24시간):